Latest News
SM Energy's stock has doubled in 2025 after its Civitas merger boosted revenue and cash flow, cut debt, and prompted a higher dividend, though risks and integration costs remain.
Via MarketBeat · September 14, 2026
IREN's AI ambitions are getting a real-world test. See what Horizon 1 changes, what must happen next, and why repeatable execution could matter more than another blockbuster contract.
Via The Motley Fool · September 14, 2026
Dennis Liu sold shares to satisfy tax withholding and a pre-scheduled trading plan, leaving him with 15,870 direct shares valued at ~$707,000.
Via The Motley Fool · September 14, 2026
A covered-call ETF’s big “yield” can hide return-of-capital and capped upside, so check the numbers that show what you’re really getting.
Via The Motley Fool · September 14, 2026
You're shaking your head, aren't you? Hear me out.
Via The Motley Fool · September 14, 2026
The Vanguard Morningstar Growth ETF is a great fund for investors who want megacap growth exposure, but it doesn't need to be paired with its S&P 500 counterpart.
Via The Motley Fool · September 14, 2026
Could the Clarity Act really become a super-catalyst for Ethereum?
Via The Motley Fool · September 14, 2026
Intel shares rallied on unconfirmed reports of a 10% CPU price hike amid tight server chip supply, prompting analyst upgrades even as MarketBeat's consensus rating remains a Hold.
Via MarketBeat · September 14, 2026
Down more than 75% from its high, Nike stock is facing big challenges.
Via The Motley Fool · September 14, 2026
The Hain Celestial Group (NASDAQ:HAIN) said it has agreed to sell its international business to private equity firm Aurelius for $323 million in cash, a transaction that would leave the company focused on a streamlined North American portfolio. The company expects the sale to close in its fiscal sec
Via MarketBeat · September 14, 2026
McKesson (NYSE:MCK) executives said the company’s first-quarter performance supported a higher full-year earnings outlook, citing broad-based growth across its North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions businesses.
Speaking at the Morgan Stanl
Via MarketBeat · September 14, 2026
AMD's 34% revenue surge and 12.5% net margin contrast sharply with ASML's 29.4% profitability and $12.3 billion in free cash flow.
Via The Motley Fool · September 14, 2026
The company has an ambitious plan to get a satellite internet constellation working by next year.
Via The Motley Fool · September 14, 2026
AT&T's stock provides investors with tremendous value as the market looks to have overreacted to the SpaceX risk.
Via The Motley Fool · September 14, 2026
One company is returning billions to shareholders while demand for its products continues to accelerate. The other is still years away from making money on the cars it sells.
Via The Motley Fool · September 14, 2026
The S&P 500 is down, but moderately, despite surging oil price and interest rates and the worsening war. Here's why.
Via Investor's Business Daily · September 14, 2026
A clear "sell" signal could arrive this year.
Via The Motley Fool · September 14, 2026
Redwire is scaling quickly, but one financial test may determine how much of that growth ultimately reaches shareholders. The latest numbers reveal what investors should watch next.
Via The Motley Fool · September 14, 2026
Royal Caribbean offers accelerating earnings and unusual forward visibility, while Walmart offers defensive scale and e-commerce momentum.
Via The Motley Fool · September 14, 2026

XAUUSD: SELL 4335.00, SL 4370.00, TP 4255.00No swaps on majors for a month! Learn moreThe main driver of the week for gold is the Fed meeting against the b
Via Talk Markets · September 14, 2026
Coca-Cola, Chevron, and Merck have outperformed the S&P 500 in 2026, each pairing strong share-price gains with growing dividends backed by solid fundamentals.
Via MarketBeat · September 14, 2026
Discover the top Ayurvedic clinic in Faridabad for holistic healing, expert doctors, and authentic Panchakarma therapies. Restore wellness naturally. Book
Via Talk Markets · September 14, 2026
The Schwab U.S. Dividend Equity ETF has been an elite performer in this category for a long time.
Via The Motley Fool · September 14, 2026
Definium Therapeutics' synthetic LSD eased the symptoms of anxiety, the company said Monday as shares took off again.
Via Investor's Business Daily · September 14, 2026
Holding out for larger checks doesn't always work out for the best.
Via The Motley Fool · September 14, 2026
